Biomarkers in medicine · 2026
The Syn-sleep trial protocol: detection of cutaneous phosphorylated alpha-synuclein in REM sleep behavior disorder.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marcotte Sarrah, Levine Todd, Freeman Roy, Gibbons Christopher H
Аннотация
BACKGROUND: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a prodromal neurodegenerative disease of misfolded alpha-synuclein (P-SYN) with a high risk of phenoconversion to a clinically apparent synucleinopathy (including Parkinson's disease, multiple system atrophy, or dementia with Lewy bodies) over 15 years.
OBJECTIVES: To determine rates of cutaneous P-SYN deposition in iRBD, to quantify changes in PSYN deposition over time, and to determine if P-SYN deposition patterns and amounts predict phenoconversion to a specific type of synucleinopathy.
CLINICAL TRIAL PROTOCOL: In a prospective, blinded study we will recruit 80 individuals with polysomnography confirmed iRBD or probable RBD using standard diagnostic criteria. Skin biopsies with dual immunohistochemical immunostaining for nerve fibers (protein gene product 9.5) and P-SYN will be completed at 3 sites using standard methodology. Quantitative measures of P-SYN and nerve fiber density will be measured blinded to any clinical data and will be followed longitudinally to determine the final clinical diagnosis.
DISCUSSION: Patients with iRBD are an important population to study due to the high rates of phenoconversion to clinically apparent synucleinopathy. Defining the frequency of P-SYN deposition and the risk of phenoconversion will aid in the development of future clinical trials that seek to alter the natural history of synucleinopathies.
OBJECTIVES: To determine rates of cutaneous P-SYN deposition in iRBD, to quantify changes in PSYN deposition over time, and to determine if P-SYN deposition patterns and amounts predict phenoconversion to a specific type of synucleinopathy.
CLINICAL TRIAL PROTOCOL: In a prospective, blinded study we will recruit 80 individuals with polysomnography confirmed iRBD or probable RBD using standard diagnostic criteria. Skin biopsies with dual immunohistochemical immunostaining for nerve fibers (protein gene product 9.5) and P-SYN will be completed at 3 sites using standard methodology. Quantitative measures of P-SYN and nerve fiber density will be measured blinded to any clinical data and will be followed longitudinally to determine the final clinical diagnosis.
DISCUSSION: Patients with iRBD are an important population to study due to the high rates of phenoconversion to clinically apparent synucleinopathy. Defining the frequency of P-SYN deposition and the risk of phenoconversion will aid in the development of future clinical trials that seek to alter the natural history of synucleinopathies.